Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial;Plaatjesaggregatieremming en angiotensine II-receptorblokkade na een TIA; de onverwachte bevindingen van het 'Prevention regimen for effectively avoiding second strokes' (PROFESS)

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 35, 2008, Pages 1907-1910

  Kappelle, L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; TELMISARTAN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DISABILITY; DRUG INDICATION; DRUG SAFETY; HEADACHE; HUMAN; NOTE; RECURRENT DISEASE; STROKE; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASPIRIN; BENZIMIDAZOLES; BENZOATES; COST-BENEFIT ANALYSIS; DIPYRIDAMOLE; HEADACHE; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTOR, ANGIOTENSIN, TYPE 2; STROKE; TICLOPIDINE;

EID: 52149100084     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Kappelle LJ, Frijns CJM. Behandeling van patiënten met een TIA of een herseninfarct. Ned Tijdschr Geneeskd. 2002;146:1678-80.
2. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetyl-salicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-39.
4. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-7.
5. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-73.
6. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17.
7. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003;34:2741-8.
8. Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Steering Committee; PRoFESS Study Group. Cerebrovasc Dis. 2007;23(Suppl 5-6):368-80.
9. Balamuthusamy S, Arora R. Hematologic adverse effects of clopidogrel. Am J Ther. 2007;14:106-12.
10. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. BMJ. 2008;336:1121-3.